Cross species single domain antibodies targeting mesothelin for treating solid tumors
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsMitchell Ho, Ira H. Pastan, Jessica D. Hong, Nan Li
Life of this patent
Estimating the term…
Abstract
Camel single-domain monoclonal antibodies that specifically bind human and mouse mesothelin are described. Chimeric antigen receptor (CAR) T cells and antibody conjugates based on the mesothelin-specific antibodies are also described. The disclosed CAR T cells, mesothelin-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of mesothelin-positive cancers.
Claims48
A single-domain monoclonal antibody that specifically binds mesothelin, wherein the monoclonal antibody comprises the complementarity determining region 1 (CDR1), CDR2 and CDR3 sequences of SEQ ID NO:
- 2 or SEQ ID NO:
- 4.
The monoclonal antibody of claim wherein:
- the CDR1, CDR2 and CDR3 sequences of the monoclonal antibody respectively comprise residues 31-35, 50-66 and 99-106 of SEQ ID NO:
- 4;
- the CDR1, CDR2 and CDR3 sequences of the monoclonal antibody respectively comprise residues 26-33, 51-58 and 97-106 of SEQ ID NO:
- 4;
- or
- the CDR1, CDR2 and CDR3 sequences of the monoclonal antibody respectively comprise residues 27-35, 47-60 and 98-106 of SEQ ID NO:
- 4.
8-9. (canceled)
13-15. (canceled)
20-24. (canceled)
(canceled)
29-30. (canceled)
33-34. (canceled)
(canceled)
57-60. (canceled)
Dependencies are inferred from the claim text.